ClinicalTrials.gg
CompletedNCT02282527Updated Mar 13, 2017Results posted

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

A Phase 2/3 interventional study of Liquid Alpha₁-PI and Prolastin-C in Alpha₁-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 6 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Grifols Therapeutics Inc. conducted a multi-center, randomized, double-blind, crossover study to evaluate the safety, immunogenicity, and pharmacokinetics (PK) of Liquid Alpha₁-PI compared to the currently licensed product, Prolastin-C, in subjects with Alpha₁-Antitrypsin Deficiency (AATD).

02

Conditions studied

  • Alpha₁-Antitrypsin Deficiency
03

In context

Lead sponsor

Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

First submitted after Grifols Therapeutics LLC became part of Grifols.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 18 and 70 years of age, inclusive
  • Had a diagnosis of congenital AATD
  • Had a documented total alpha₁-PI level \< 11 µM. If the total alpha₁-PI level had yet to be documented, a blood draw for total alpha₁-PI level was obtained at the Screening Visit
  • Had a post-bronchodilator (FEV1) ≥ 30% and \< 80% of predicted and FEV1/forced vital capacity (FVC) \< 70%
  • If the subject had received alpha₁-PI augmentation therapy of any kind, he/she must have been be willing to discontinue that treatment at the Week 1 (Baseline) Visit and remain off any kind of alpha₁-PI treatment, other than the products for this study, while participating in the study

Exclusion criteria

Exclusion Criteria:

  • Subject had a moderate or severe pulmonary exacerbation during the 4 weeks before the Week 1 (Baseline) Visit
  • History of lung or liver transplant
  • Any lung surgery during the past 2 years (excluding lung )
  • Liver cirrhosis confirmed by biopsy
  • Elevated liver enzymes ( [AST], alanine aminotransferase [ALT], and alkaline phosphatase [ALP]) equal to or greater than 2.5 times the
  • Severe concomitant disease (e.g., congestive heart failure, pulmonary fibrosis, malignant disease [with the exception of skin cancers other than melanoma], history of acute pneumonitis reaction, or current chronic hypersensitivity pneumonitis)
  • Females who were pregnant, breastfeeding or, if of , unwilling to practice a highly effective method of (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or abstinence) throughout the study
  • Known previous infection with or clinical signs and symptoms consistent with current hepatitis A virus (HAV), virus (HBV), virus (HCV), or (HIV) infection
  • Smoking during the past 6 months or a positive urine cotinine test at the Screening Visit that is due to smoking
  • Participation in another drug study within one month prior to the Week 1 (Baseline) Visit
  • History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s)
  • Use of systemic above a stable dose equivalent to 5 mg/day prednisone (i.e.,10 mg every 2 days) within the 4 weeks prior to the Week 1 (Baseline) Visit inhaled steroids are not considered systemic steroids)
  • Use of systemic or aerosolized antibiotics for an exacerbation within the 4 weeks prior to the Week 1 (Baseline) Visit
  • Known selective or severe Immunoglobulin A (IgA) deficiency
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Other
    Treatment Sequence 1

    Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C

    Biological: Liquid Alpha₁-PI · Biological: Prolastin-C

  • Other
    Treatment Sequence 2

    Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI

    Biological: Liquid Alpha₁-PI · Biological: Prolastin-C

Interventions

  • BiologicalLiquid Alpha₁-PI

    Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions

  • BiologicalProlastin-C

    Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions

06

What researchers measure

Primary outcomes

  1. AUC(0-7 Days) Based on Antigenic Content

    The primary PK objective of this study was to demonstrate the bioequivalence of Liquid Alpha₁-PI 60 mg/kg to Prolastin-C 60 mg/kg, as measured by AUC from 0 to 7 days (AUC0-7days) using an antigenic content assay of alpha₁-PI, at approximate steady state in subjects with AATD.

    Time frame: pre-dose, 0, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 5 days, 7 days post dose

Secondary outcomes

  1. AUC(0-7 Days) Based on Functional Activity

    The exploratory PK objective of this study was to demonstrate the bioequivalence of Liquid Alpha₁-PI 60 mg/kg to Prolastin-C 60 mg/kg, as measured by AUC from 0 to 7 days (AUC 0-7 days) using a functional activity assay of alpha₁-PI, at approximate steady state in subjects with AATD.

    Time frame: pre-dose, 0, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 5 days, 7 days post dose

  2. Number of Subjects With Immunogenicity Response

    Blood samples for immunogenicity testing were collected at Weeks 1 (Baseline), 9, 17, and 20. Any samples that tested positive for alpha₁-PI antibodies were tested for neutralizing antibodies and antibody titer. Immunogenicity testing was performed using validated assays in a multitiered approach. Samples collected at Week 1 (Baseline) and at Weeks 9 and 20 were tested for immunogenicity while samples collected at Week 17 were to be tested for immunogenicity only if deemed appropriate (eg, unexpected PK profile).

    Time frame: Weeks 1, 9, 17, and 20

07

Results

Posted Mar 13, 2017

Participant flow

This study was performed at 6 investigative centers in the US.

Participant flow — Overall Study
MilestoneLiquid Alpha₁-PI/Prolastin-CProlastin-C/Liquid Alpha₁-PI
Started1616
Completed1515
Not completed11
Withdrew: Lost to follow-up01
Withdrew: Lack of home health aid10

Outcome measures

PrimaryAUC(0-7 Days) Based on Antigenic Content

The primary PK objective of this study was to demonstrate the bioequivalence of Liquid Alpha₁-PI 60 mg/kg to Prolastin-C 60 mg/kg, as measured by AUC from 0 to 7 days (AUC0-7days) using an antigenic content assay of alpha₁-PI, at approximate steady state in subjects with AATD.

Time frame:
pre-dose, 0, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 5 days, 7 days post dose
Reported as:
Mean · mg*h/mL
AUC(0-7 Days) Based on Antigenic Content
mg*h/mLLiquid Alpha₁-PIProlastin-C
AUC(0-7 Days) Based on Antigenic Content203.20 ± 23.041198.38 ± 25.230
SecondaryAUC(0-7 Days) Based on Functional Activity

The exploratory PK objective of this study was to demonstrate the bioequivalence of Liquid Alpha₁-PI 60 mg/kg to Prolastin-C 60 mg/kg, as measured by AUC from 0 to 7 days (AUC 0-7 days) using a functional activity assay of alpha₁-PI, at approximate steady state in subjects with AATD.

Time frame:
pre-dose, 0, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 5 days, 7 days post dose
Reported as:
Mean · mg*h/mL
AUC(0-7 Days) Based on Functional Activity
mg*h/mLLiquid Alpha₁-PIProlastin-C
AUC(0-7 Days) Based on Functional Activity171.16 ± 28.764168.50 ± 27.473
SecondaryNumber of Subjects With Immunogenicity Response

Blood samples for immunogenicity testing were collected at Weeks 1 (Baseline), 9, 17, and 20. Any samples that tested positive for alpha₁-PI antibodies were tested for neutralizing antibodies and antibody titer. Immunogenicity testing was performed using validated assays in a multitiered approach. Samples collected at Week 1 (Baseline) and at Weeks 9 and 20 were tested for immunogenicity while samples collected at Week 17 were to be tested for immunogenicity only if deemed appropriate (eg, unexpected PK profile).

Time frame:
Weeks 1, 9, 17, and 20
Reported as:
Count of participants · Participants
Number of Subjects With Immunogenicity Response
ParticipantsLiquid Alpha₁-PI/Prolastin-CProlastin-C/Liquid Alpha₁-PI
Number of Subjects With Immunogenicity Response00

Adverse events

Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liquid Alpha₁-PI—0/32 (0%)9/32 (28.1%)
Prolastin-C—1/31 (3.2%)3/31 (9.7%)
Most frequent serious events
Most frequent serious events
EventLiquid Alpha₁-PIProlastin-C
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations0/321/31
Most frequent other events
Most frequent other events
EventLiquid Alpha₁-PIProlastin-C
NasopharyngitisInfections and infestations1/322/31
FatigueGeneral disorders2/320/31
PyrexiaGeneral disorders2/320/31
DiarrhoeaGastrointestinal disorders2/321/31
Dermatitis ContactSkin and subcutaneous tissue disorders2/320/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)Liquid Alpha₁-PI/Prolastin-CProlastin-C/Liquid Alpha₁-PITotal
Mean60.7 ± 7.9463.1 ± 5.9361.9 ± 7.00
Sex: Female, Male
Sex: Female, Male(Participants)Liquid Alpha₁-PI/Prolastin-CProlastin-C/Liquid Alpha₁-PITotal
Female8614
Male81018
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Liquid Alpha₁-PI/Prolastin-CProlastin-C/Liquid Alpha₁-PITotal
Hispanic or Latino011
Not Hispanic or Latino161531
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Liquid Alpha₁-PI/Prolastin-CProlastin-C/Liquid Alpha₁-PITotal
United States161632
Alpha1-PI concentration
Alpha1-PI concentration(mg/mL)Liquid Alpha₁-PI/Prolastin-CProlastin-C/Liquid Alpha₁-PITotal
Naive0.31 ± NA0.21 ± 0.0400.24 ± 0.059
Non-naive0.72 ± 0.2830.69 ± 0.2150.70 ± 0.248
08

Study locations

6 sites
  • National Jewish Health
    Denver, Colorado 80206, United States
  • University of Florida Gainesville
    Gainesville, Florida 32610, United States
  • University of Miami - Miller School of Medicine
    Miami, Florida 33136, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Texas Health Science Center
    Tyler, Texas 75708, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2014
First posted
Nov 4, 2014
Start
Oct 2014
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Mar 13, 2017
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02282527
Responsible party
Sponsor
First posted
Nov 4, 2014
Start date
Oct 2014
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Mar 13, 2017
Last update
Mar 13, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion